摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-dimethyltetrahydro-2-pyrone | 78094-66-3

中文名称
——
中文别名
——
英文名称
4,5-dimethyltetrahydro-2-pyrone
英文别名
4,5-dimethyl-3,4,5,6-tetrahydropyran-2-one;4,5-Dimethyloxan-2-one
4,5-dimethyltetrahydro-2-pyrone化学式
CAS
78094-66-3;78148-69-3;78148-72-8;87860-32-0;116257-96-6;136235-72-8
化学式
C7H12O2
mdl
——
分子量
128.171
InChiKey
MNSSPGUFOSPVSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    219.4±8.0 °C(Predicted)
  • 密度:
    0.956±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    4,5-dimethyltetrahydro-2-pyrone氢溴酸 作用下, 以 乙醇 为溶剂, 以71%的产率得到5-Bromo-3,4-dimethyl-pentanoic acid ethyl ester
    参考文献:
    名称:
    (3 S,4 R / 3 R,4 S)-和(6 E,10 Z)-3,4,7,11-四甲基-trideca-6,10-二烯丙基(6 E,10 Z)的非对映异构混合物的立体选择性全合成法拉纳尔); 法老的蚂蚁的踪迹信息素
    摘要:
    外消旋的(3 S,4 R / 3 R,4 S)-呋喃醛[(1a)+(1b)]已通过聚合的立体定向途径合成,该途径采用在末端乙炔上添加烷基铜配合物,生成两个三取代的双键和Diels-Alder反应建立C-3,C-4甲基的相对立体化学。富含(3 S,4 S / 3 R,4 R)-对映异构体对[(1c)+(1d)]的法拉那尔的非对映异构混合物,是通过中间体二酯通过较短的路线合成的,该中间体由巴豆酸乙酯的电化学二聚。
    DOI:
    10.1039/p19830001387
  • 作为产物:
    描述:
    3-hydroxy-3,6-dihydro-2H-pyran-2-one正丁基锂六甲基二硅氮烷lithium chloride 、 zinc dibromide 作用下, 以 四氢呋喃 为溶剂, 反应 9.75h, 生成 4,5-dimethyltetrahydro-2-pyrone
    参考文献:
    名称:
    A Rapid Divergent Synthesis of Highly Substituted δ-Lactones
    摘要:
    Nucleophilic 1,2-addition of (Z)-gamma-silyloxyvinylzinc reagents to ethyl glyoxylate followed by desilylation and cyclization affords 3,6-dihydro-3-hydroxypyran-2-ones in good chemical yields. In situ formation of allylic phosphates followed by reaction with RCu(CN) Li reagents affords substituted 5,6-dihydropyran-2-ones. The parent compound, 3,6-dihydro-3-hydroxypyran-2-one, undergoes allylic phosphate formation, cuprate-mediated allylic substitution, and 1,4-conjugate addition to afford trans-4,5-disubstituted tetrahydropyran-2-ones in a one-pot process.
    DOI:
    10.1021/ol0617695
点击查看最新优质反应信息

文献信息

  • Method for producing optically active alcohols or carboxylic acids
    申请人:Urtel Heiko
    公开号:US20070135648A1
    公开(公告)日:2007-06-14
    The present invention relates to a process for preparing optically active hydroxy-, alkoxy-, amino-, alkyl-, aryl- or chlorine-substituted alcohols or hydroxy carboxylic acids having from 3 to 25 carbon atoms or their acid derivatives or cyclization products by hydrogenating the correspondingly substituted optically active mono- or dicarboxylic acids or their acid derivatives in the presence of a catalyst whose active component consists of rhenium or of rhenium and comprises at least one further element having an atomic number of from 22 to 83, with the provisos that a. the at least one further element having an atomic number of from 22 to 83 is not ruthenium and b. in the case of the preparation of optically active 2-amino-, 2-chloro-, 2-hydroxy- and 2-alkoxy-1-alkanols by catalytically hydrogenating corresponding optically active 2-aminocarboxylic acids, 2-chlorocarboxylic acids, 2-hydroxycarboxylic acids and 2-alkoxycarboxylic acids or their acid derivatives, the at least one further element having an atomic number of from 22 to 83 is not palladium or platinum.
    本发明涉及一种制备具有3至25个碳原子的光学活性羟基、烷氧基、氨基、烷基、芳基或氯取代醇或羟基羧酸或其酸衍生物或环化产物的过程,通过在催化剂存在下氢化相应取代的光学活性单或二羧酸或其酸衍生物,所述催化剂的活性组分由铼或铼组成,并包括至少一种原子序数为22至83的进一步元素,条件是a. 原子序数为22至83的至少一种进一步元素不是钌和b. 在通过催化氢化相应的光学活性2-氨基、2-氯、2-羟基和2-烷氧基-1-烷醇来制备相应的光学活性2-氨基羧酸、2-氯羧酸、2-羟基羧酸和2-烷氧基羧酸或其酸衍生物时,原子序数为22至83的至少一种进一步元素不是钯或铂。
  • Hydrogenation method for producing optically active alcohols or carboxylic acids
    申请人:Urtel Heiko
    公开号:US20070142648A1
    公开(公告)日:2007-06-21
    The present invention relates to a process for preparing optically active hydroxy-, alkoxy-, amino-, alkyl-, aryl- or chlorine-substituted alcohols or hydroxy carboxylic acids having from 3 to 25 carbon atoms or their acid derivatives or cyclization products by hydrogenating the correspondingly substituted optically active mono- or dicarboxylic acids or their acid derivatives in the presence of a catalyst whose active component comprises a noble metal selected from the group of the metals Pt, Pd, Rh, Ir, Ag, Au and at least one further element selected from the group of the elements: Sn, Ge, Mo, W, Ti, Zr, V, Mn, Fe, Co, Ni, Cu, Zn, Ga, In, Pb, Bi, Cr, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
    本发明涉及一种制备具有3至25个碳原子的光学活性羟基、烷氧基、氨基、烷基、芳基或氯取代醇或羟基羧酸或其酸衍生物或环化产物的过程,通过在存在催化剂的情况下,将相应取代的光学活性单酸或二酸或其酸衍生物加氢,所述催化剂的活性组分包括从铂、钯、铑、铱、银、金等金属组成的贵金属中选择的一种金属以及从锡、锗、钼、钨、钛、锆、钒、锰、铁、钴、镍、铜、锌、镓、铟、铅、铋、铬、铈、镨、钕、钷、钐、铕、钆、铽、镝、钬、铒、铥和镱等元素组成的至少一种其他元素。
  • Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
    申请人:Research Triangle Institute
    公开号:US11292783B2
    公开(公告)日:2022-04-05
    Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.
    本发明公开了式(I)的强效阿片受体拮抗剂及其作为治疗抑郁症、焦虑症、精神分裂症、饮食失调以及可卡因、甲基苯丙胺、尼古丁、酒精和阿片剂成瘾的药物疗法的用途。 更具体地说,本公开提供了强效和选择性卡巴阿片受体拮抗剂化合物、这些化合物的药物组合物以及这些化合物在改善或治疗成瘾、饮食失调等方面的用途。
  • TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS
    申请人:Research Triangle Institute
    公开号:EP3512832B1
    公开(公告)日:2021-05-19
  • Tetrahydroisoquinoline Kappa Opioid Antagonists
    申请人:Research Triangle Institute
    公开号:US20190263781A1
    公开(公告)日:2019-08-29
    Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.
查看更多